Mans International “Be Your Own Boss” Program is designed to help people from all walks of life around the world who are committed to changing their way of thinking, improving their abilities, and achieving financial freedom and time freedom.
Before You Start
First of all, I’m sorry to tell you that it takes a long time to realize financial freedom and time freedom. If for whatever reason, you have obtained a large amount of wealth, it doesn’t mean that you achieved financial freedom automatically. Because you may not have the ability and psychological capacity to manage large amounts of wealth, the money will be consumed at a rate you can’t imagine.
You might say, can I just ask a financial professional to help me take care of my wealth? The question I asked was do you have the ability to select an outstanding and suitable professional?
If you feel that you ALREADY have independent thinking and various skills, then you do not need to participate in this program! All the best!
Our Values
If you DON’T agree with our values, please do not disturb！
Check Mans International “Be Your Own Boss” program values:
You can either send an email to info@mansinternational.com and we will send you the latest content regularly.
Before You Go
Every year we make plans. Every day we receive tons of information and learn a lot of knowledge, but why most people still can’t make choices that are beneficial to themselves in the long run, achieve their goals, and become a better version of themselves?
Here is the signal most founders and investors missed:
A Chinese AI company reportedly raised US$7.4 billion at around a US$50 billion valuation, cracking the global top 15 unicorns.
That company is DeepSeek — one of China’s most watched AI labs, known for challenging the global AI race with high-performing, cost-efficient large language models.
Yet after reportedly closing a massive funding round of over US$7.4 billion, or 50 billion RMB, its immediate next move was not simply a public computing-power expansion or another race to cut parameter costs. Instead, it launched a comprehensive hiring wave across 7 categories and 33 roles.
Among them, one role deserves particular attention from founders and investors: Emotional Intelligence Data Product Manager.
The core responsibility of this role is about turning complex, ambiguous human emotions and intentions into evaluation systems, training workflows, and product feedback loops.
The Next AI Battle Is Not Only Model IQ. It Is Scenario EQ.
Through the lens of SMAF — Scenario Maturity Assessment Framework, our active framework to stress-test an AI company’s commercial ecosystem and value-capture architecture, DeepSeek’s hiring signal points to a deeper shift:
The next phase of AI commercialization will not be won only by higher model IQ. It will be won by stronger scenario EQ.
Can the AI detect when a customer is truly angry? Can it understand when a patient says “I’m fine,” but is actually anxious, confused, or losing trust? Can it recognize when a buyer says “let us think about it,” but the real blocker is budget, internal politics, risk perception, or cultural mismatch?
These are not simple sentiment-analysis problems. They are scenario-maturity problems.
Emotional Intelligence Is a Data Maturity Problem
In SMAF, data maturity does not mean owning more data. It means the ability to convert messy, fragmented, non-standard signals from real use cases into a repeatable loop:
This is precisely why the “Emotional Intelligence Data Product Manager” is an essential marker for founders and institutional investors. This is not an abstract, soft-skill humanities role; it is a hard commercial signal. AI is graduating from the basic tool phase of answering questions to the complex scenario phase of decoding human intent.
Furthermore, as AI leaders shift from model-centric competition to usage-efficiency and token-economics discipline, scenario accuracy becomes a direct P&L issue. High Scenario EQ means fewer wasted interactions, fewer misinterpreted prompts, fewer repeated explanations, and fewer costly friction loops.
In enterprise AI, understanding the scenario correctly is not merely a product advantage but a path to more sustainable profitability.
The Mans International View: East–West Scenario Splintering
Technology may travel globally, but emotional intelligence does not move across markets in a straight line.
The same underlying model capability can face completely different maturity paths in North America, China, and other markets. I call this Scenario Splintering: when one technology enters different cultural, regulatory, workflow, and business environments — and each environment demands a different product logic.
The US Paradigm (Persona & Deep Alignment): Pioneers like Character.ai and Replika established an early blueprint for highly individualized relationship building, utilizing Conversation Designers, Psychology Researchers, and Dialogue Data Experts to curate explicit “personas” and empathetic baselines.
The China Paradigm (Rapid Vertical Embedding): Domestic players like Emoha (聆心智能) trained models directly on clinical counseling data to deploy its series across over 600 specific mental health, university, and enterprise scenarios. Following its integration with Zhipu to power CharacterGLM, the priority shifted to cross-ecosystem scale — immediately embedding empathetic capabilities into gaming NPCs, virtual companions, and digital human assets to maximize immediate commercial velocity.
The Strategic Trap: Copy-pasting Western “clinical AI” to the East usually dies because users won’t pay for a “diagnostic” experience. Pushing Eastern “heavy-companion AI” to the West usually dies under privacy scrutiny. Cross-border Emotional AI requires Scenario Reconstruction (Cultural Translation), not just code translation.
The Woebot Reality Check
Look at Woebot Health. Despite its Stanford roots and FDA breakthrough designation, it has struggled to build a sustainable commercial flywheel.
Under the SMAF lens, this is a classic case of misalignment in narrative, workflow, and business model maturity. While their clinical narrative was strong, their workflow maturity struggled to seamlessly integrate into existing fragmented healthcare systems, and their business model faced friction reconciling the high costs of medical compliance with shifting B2B enterprise budgets. Having the best clinical design doesn’t matter if the commercial scenario isn’t mature enough to sustain the business.
Execution is becoming easier. Scenario Intelligence is becoming more valuable.
At Mans International, this is the core of our SMAF work: helping founders, investors, and cross-border technology teams evaluate whether a promising AI product has matured enough to become a real commercial system.
If you are currently building the next generation of affective interfaces, or orchestrating a cross-border tech launch between Western innovation and Eastern scale, look beyond the leaderboard benchmarks.
Contact Mans International to schedule a private, selective Scenario Maturity Audit. Let’s assess your structural gaps and secure your commercial roadmap before your next major deployment.
The I Ching (Book of Changes) states: “Heaven’s movement is ever vigorous; thus, the noble person constantly strives for self-improvement.” This underlying force of relentless self-renewal, regardless of the circumstances, has found its most extreme validation in the practice of Mr. Cai Lei.
An ALS breakthrough: A master class in Deep-Tech Ecosystem Building, Founder Resilience, and SMAF
In 2019, Mr. Cai Lei, a former vice president of JD.com and one of the pioneers behind China’s electronic invoice system, was diagnosed with amyotrophic lateral sclerosis, or ALS. He was 41. He had just welcomed a new child. His career, family, and life were all at a peak moment.
Then came the diagnosis. ALS is often described as one of the most devastating neurodegenerative diseases. The average survival window after diagnosis is often only a few years.
Seven years later, in 2026, his body function score plummeted from 48 to 4. He is completely paralyzed from the neck down, his vocal cords have severely atrophied, and he relies on a liquid diet and a 24-hour ventilator to survive. Across his entire body, only his eyes remain under his autonomous control.
Cai Lei before and after ALS
Yet, Cai Lei’s story is far more than an inspiring narrative of resilience and empathy. Analyzed through the Scenario Maturity Assessment Framework (SMAF), it stands as a textbook masterclass in deep-tech scenario breakthroughs. It is a blueprint of how to take a globally recognized “unsolvable dead end” and reconstruct it into a high-maturity, self-sustaining ecosystem of research collaboration and commercial translation.
I. Deconstructing the Breakthrough via SMAF: A High-Maturity Super Ecosystem
At Mans International, we utilize the SMAF (Scenario Maturity Assessment Framework) to evaluate the commercial viability and translation potential of deep tech ventures. We have seen too many projects perish in the “slide deck” phase or or “lab-only self-indulgences.”
From a scenario maturity perspective, the true brilliance of Cai Lei’s “ice-breaking” initiative is not simply his unwavering belief, but his methodical execution. He took a highly fragmented, chronically inefficient rare-disease scenario — one lacking adequate resource attention — and orchestrated it into a synchronized system uniting patients, data, research, clinical trials, capital, AI, and public trust.
1. Data and Workflows: From Scattered Patients to R&D Infrastructure
One of the greatest bottlenecks in rare disease R&D is scattered patient populations, scarce biological samples, and a lack of real-world data. Often, research does not lack direction; it lacks a stable, continuous, and actionable data foundation.
The Data Engine: Cai Lei built the “Jianyu Mutual Aid Home,” the world’s largest civilian ALS research database (over 18,000 registered users), housing tens of thousands of structured real-world cases. He also launched an “ALS Research AI Brain,” training 24/7 on over 20 million interdisciplinary papers to automatically filter and evolve targets without burdening researchers.
The Workflow: This 360-degree dynamic vital-sign tracking system compresses notoriously slow clinical recruitment to astonishing speeds — achieving “hour-level” responsiveness (i.e. 700 sign-ups in 2 hours; launching clinical trials within 3 months).
Data and Workflows: From Scattered Patients to R&D Infrastructure
2. The Business Closed Loop: A Mechanism for Long-Term Sustenance
Rare disease research cannot survive solely on short-term donations or one-off grants. Drug discovery features long cycles, high failure rates, and relentless capital demands, while external funding environments and public attention fluctuate. Without a stable financial engine, even the grandest mission will bleed out mid-way.
The partnership forged between Cai Lei and his wife, Duan Rui, perfectly demonstrates the synergy of vision and operations. Many view Duan Rui’s live-streaming efforts purely as a “wife’s sacrifice.” While deeply moving and true, from a strategic perspective, it is a brilliantly designed commercial closed loop.
Cai Lei continually raises the ceiling of their mission — connecting patients, scientists, pharma, and society. Meanwhile, Duan Rui absorbs the immense operational realities: live-streaming revenue, team management, cash flow, cost control, and risk mitigation. This closed-loop of “front-end commercial revenue funding back-end R&D burn” provides a continuous lifeline for a highly uncertain, long-cycle scientific endeavour.
The Business Closed Loop: A Mechanism for Long-Term Sustenance
3. Narrative & Ecosystem: Evolving from Empathy to Industry Consensus
Before Cai Lei, ALS was trapped in a weak narrative within public and industry discourse — viewed merely as an “incurable and unprofitable” tragedy. It garnered generalized sympathy but lacked actionable pathways.
Cai Lei elevated this narrative fundamentally. He did not stop at emotional appeals for awareness; he broke down rare-disease R&D into actionable industry propositions. He allowed the scientific community, the biotech industry, and the public to clearly see their specific roles and value.
This mature narrative has penetrated industry silos, uniting over 60 global research teams and 50+ biotech companies, transforming an untouched “cold sector” into a highly coordinated battlefield with shared consensus, pooled resources, and a synchronized tempo.
Narrative & Ecosystem: Evolving from Empathy to Industry Consensus
II. The Founder’s Mirror: Resilience for Global Founders
In his recent “Countdown” speech on Global ALS Day, June 21, 2026, Cai Lei said he had already defeated an enemy more terrifying than ALS: despair.
For founders today — navigating agonizing market cycles and high-stakes survival tests — Cai Lei’s mental fortitude serves as a profound mirror:
Reject the Victim Mentality. Complaining about the macro environment or the “capital winter” yields zero value. Completely paralyzed and unable to speak, Cai Lei never wallowed in the unfairness of fate. He immediately pivoted his strategy, utilizing an eye-tracking device to launch a race against time. Radical acceptance and execution to the absolute limit are the foundational ethics of a founder.
Pry Open Incremental Gaps in Dead Ends. Cai Lei noted: “You might think there is only a solid wall in front of you. But look down, there might be a path; turn sideways, there is a gap. You can even choose to climb over or dig through.” When traditional funding tightens and cross-border barriers rise, a founder’s core competency is leveraging tools — like AI and cross-disciplinary ecosystems — to pry open growth spaces ignored by the mainstream.
Anchor Your Venture in a Grand Proposition.“The best way to overcome fear is to place yourself within a much greater cause.” When your corporate vision is tied to core societal challenges — hard tech breakthroughs, life sciences, energy transitions — the resilience you unlock will far surpass what secular fame or profit can sustain.
Pry Open Incremental Gaps in Dead Ends
III. Conclusion: The Countdown is a Prelude to Victory
In Cai Lei’s room, four clocks sit ticking. The media calls it the countdown of his life. He corrects them: “This is my countdown to ALS.”
“If my eyes fail, I will connect to a Brain-Computer Interface. If my brain stops turning, I will upload my consciousness to an embodied robot. I have marched all the way to the face of this terminal illness, and I am not here to surrender.”
As heaven’s movement is ever vigorous, so must a leader ceaselessly strive along.
The Countdown is a Prelude to Victory
Here is to all the founders who keep walking through the valleys of economic cycles. Here is to the researchers grinding relentlessly in their labs. Here is to all those who refuse to bow to fate.
Do not ask where the hope lies. Keep moving forward, and hope will reveal itself. As long as you do not retreat, every direction is the way forward.
Global Strategic Partnership
Leading global research institutions, multinational pharmaceutical companies, biotech innovators, and international funds are invited to partner with Mans International to access and navigate high-maturity life science and deep-tech ecosystems.
Through our SMAF — Scenario Maturity Assessment Framework — we help identify where technology, capital, clinical resources, market readiness, and ecosystem trust can be precisely aligned.
Our goal is to reduce cross-border and cross-sector friction, accelerate clinical and commercial translation, and support breakthrough technologies and strategic capital in moving from promise to real-world impact.
While Elon Musk packages “infrastructure + AI” into a grand capital narrative, China’s humanoid robotics sector is executing a dual-track playbook.
Unitree drives the market through cost disruption. Agibot drives it through strategic narrative and embodied intelligence.
Through the Scenario Maturity Assessment Framework, or SMAF, these two companies are not just robotics competitors. They represent two different answers to the same strategic question: How does a humanoid robot move from technical spectacle to commercial readiness?
Playbook A: Unitree’s “Cost Shock”
Unitree’s breakthrough is industrial, not just technical.
Leveraging China’s mature electric vehicle (EV) supply chain, they’ve driven humanoid pricing below $20,000 — shifting the market psychology from “futuristic tech demo” to “purchasable hardware.”.
In SMAF terms, this reflects world-class execution in Supply Chain Maturity and Commercial Disruption Potential. It lowers the barrier for widespread developer experimentation while forcing high-cost global competitors onto the defensive.
Unitree’s “Cost Shock”
However, cheap hardware does not guarantee a valuation premium. For enterprise buyers, the real question is:
Can it work reliably inside my operation, reduce labor burden, avoid safety issues, integrate with existing systems, and produce measurable ROI?
If a robot requires a human “babysitter” to constantly reset, maintain, or supervise it, the ROI evaporates.
The real cost isn’t the hardware. It’s the operational burden.
Unitree’s next survival test: Can we make it reliable enough that customers never regret deploying it?
Playbook B: Agibot’s Narrative-Maturity Bet
Rather than competing purely on cost, Agibot is leading with an embodied AI vision: robots that learn, adapt, and improve through real-world deployment.
In SMAF terms, Agibot exhibits strong Narrative Maturity — the ability to translate complex technology into a credible, investable story about AI entering the physical world.
Agibot’s Narrative-Maturity Bet
Its maturity profile looks very different from Unitree’s:
Narrative Maturity: Strong. Positioning embodied AI as a new intelligence layer for physical work is easy for investors to grasp, granting Agibot a higher valuation ceiling.
Workflow Maturity: Testing. Agibot is moving from demos to real industrial environments to expose hidden frictions. However, field training is not scenario maturity. Performing a single task creates excitement; becoming a reliable, low-friction production tool creates purchasing confidence.
Business Maturity: Expectation-Driven. Agibot’s commercial viability hinges on a Starlink-style data flywheel: deployment → task data → better intelligence → broader deployment. If successful, they are not just selling hardware — they are building a compounding intelligence system.
The SMAF Strategic Warning: The higher the narrative maturity, the greater the pressure for scenario validation. A compelling story secures capital, but it cannot permanently replace workflow proof.
The Cultural Bridge: Why These Two Paths?
These playbooks reflect two deeper instincts within China’s technology ecosystem:
Unitree represents supply-chain alchemy. Forged in China’s brutal EV price wars, Forged in the brutal NEV price wars, it turns mature industrial capacity into a global price shock. Unitree is trying to win by industrializing the body.
Agibot represents leapfrog ambition. Aligned with national priorities for AI-driven industrial upgrades, Agibot bets that software and data can compress years of mechanical refinement. They are attempting to win by accelerating the brain.
While one path begins with manufacturing maturity and the other with intelligence ambition, both eventually face the same question: Can the robot become useful inside real workflows?
The Imperative for Founders and Investors
Cost shocks open markets. Narrative maturity lifts valuation ceilings. Data loops create compounding power. But both companies must ultimately achieve Workflow Maturity — the threshold where demos become adoption, deployment earns trust, and technology justifies a valuation premium.
The Imperative for Founders and Investors
The Lesson for Founders:
Do not confuse technical capability with commercial readiness.
Do not confuse low cost with customer value.
Do not confuse a strong narrative with scenario maturity.
Do not confuse deployment with true adoption.
The Diligence Test for Investors:
Which company is not just building a better machine, but entering the more mature scenario?
Valuation power won’t belong to the cheapest robot or the most ambitious story. It will belong to the company that proves its robot reduces friction and generates measurable ROI.
That is the core lesson of China’s dual-track embodied AI playbook.
And it is exactly why I built the Scenario Maturity Assessment Framework (SMAF): to help founders and investors identify the gap between technical ambition and scenario maturity before the market does.
In Week 1 of the Mans International SMAF Sprint 2026, I revisited Insilico Medicine to stress-test the AI-drug premium. The conclusion was clear: the premium is no longer given for technical ambition; it must be earned through measurable scenario maturity.
This week, the SMAF Compass™ 2.0 moves from AI biotech to space infrastructure, frontier AI, and physical robotics.
The case is SpaceX. Through the SMAF lens, the IPO is a scenario-premium case: where investors are being asked to price several maturity layers at once.
Starlink is the current commercial maturity anchor.
Starship is the future capacity promise.
xAI and Grok are the AI imagination layer — but also the unresolved maturity gap.
This raises a harder question: Can mature infrastructure scenarios carry less mature AI scenarios inside the same valuation premium?
That is where the Scenario Maturity Assessment Framework, or SMAF Compass™, becomes useful.
Deconstructing the SpaceX Bundle via the SMAF Lens
A traditional IPO asks investors to value a business. The SpaceX IPO asks investors to value a system: reusable launch, Starlink, Starship, xAI, and the broader Musk narrative.
Deconstructing the SpaceX Bundle via the SMAF Lens
Starlink is the Anchor
Business Maturity: Starlink is the undisputed commercial anchor of the IPO. It has translated deep-tech capability into high-margin, recurring global revenue. From maritime communication and enterprise backup to national defense resilience, the pain point is urgent, the buyer is clear, and the value-capture path is proven. Without Starlink’s business maturity, the broader IPO valuation would be highly fragile.
Data Maturity: Starlink creates a compounding intelligence loop. More users and traffic generate richer network data, which improves routing, reliability, and performance. Better performance increases adoption, and greater adoption deepens the data advantage.
Starlink is the Anchor
Starship is the Capacity Promise
Narrative Maturity: Starship nails this pillar. It gives the market a canvas for its grandest space-based imagination — lunar missions, orbital data centres, and Mars colonization. It converts staggering technical complexity into a highly memorable story of future capacity optionality.
Starship is the Capacity Promise
However, while its Narrative Maturity is maximum, its short-term Business Maturity remains an unproven future option.
xAI is the Unresolved Layer
Workflow Maturity: This is the core maturity gap in the bundle. xAI and Grok inject a massive “AI imagination premium” into the valuation. Yet, serious enterprise and government users still face immense workflow friction: model differentiation, data trust, and deep operational integration.
xAI is the Unresolved Layer
Right now, a highly mature infrastructure scenario (Starlink) is actively carrying a far less mature workflow scenario (xAI) inside the same valuation story.
The Strategic Takeaway for Founders and VCs
Capability shock is not scenario maturity.
A technology company becomes truly investable only when the surrounding scenario matures enough to absorb the innovation and convert it into durable, compounding value.
When evaluating your own tech stack or investment pipeline this quarter, step away from technical specs and ask the tough SMAF questions:
What is your business maturity anchor? What working scenario is generating the predictable revenue needed to subsidize your future bets?
Is your narrative outpacing your workflow? If your Narrative Maturity is a 10, but your Workflow Maturity is a 2, your valuation premium is dangerously fragile.
In the frontier tech era, technology maturity is merely the baseline for entry. Scenario maturity is where the premium is actually earned.
Scenario Maturity is the Premium
Join the Mans International SMAF Sprint 2026
This assessment is Week 2, Case Study 02 of the Mans International SMAF Sprint 2026.
If you are a tech founder, deep-tech VC, industrial leader, or cross-border strategy decision-maker navigating AI, robotics, space infrastructure, or US-China technology decoupling, do not wait for the market to expose the gap.
Your technology may be strong. Your narrative may be compelling. But if the scenario is not mature enough, adoption, revenue, and valuation will eventually break under pressure.
Let’s identify the strategic gaps before the market corrects them.
Send us a direct message to request the proprietary SMAF Compass™ Briefing.
Insilico Medicine and the AI-Drug Premium: A SMAF Stress Test
I first analyzed Insilico Medicine in my 2023 book, when it became one of the most visible pioneers in AI-driven drug discovery.
By 2025, Insilico’s narrative moved beyond sheer R&D velocity. It had become a test of whether AI could translate biological insight into clinically meaningful, commercially viable assets in longevity and age-related disease — through tools like PreciousGPT and its lead asset, Rentosertib.
In 2026, the story became more complex.
Despite a milestone-based Eli Lilly collaboration worth up to $2.75 billion, including a $115 million upfront payment, Insilico’s public-market narrative remains under pressure after a $352.3 million net loss for 2025 and sharp volatility on the HKEX.
That is why I chose Insilico Medicine as an early case for the Mans International SMAF Sprint 2026.
Mans International SMAF Sprint 2026
For founders, the lesson is clear: In AI commercialization, technology maturity does not always coincide with business maturity, capital-market confidence, governance credibility, or narrative maturity.
This is exactly the kind of mismatch the Scenario Maturity Assessment Framework, or SMAF, is designed to examine.
1. Business and Narrative Maturity: “AI-Discovered Drug” Is No Longer Enough
Insilico’s real breakthrough was not simply using AI to discover drugs. It was translating a broad technology promise into a concrete business scenario.
“Aging” itself is not an FDA indication. To build a credible path to market, companies must convert broad healthspan ambition into specific diseases, measurable endpoints, and regulatory logic that investors, pharma partners, and clinicians can evaluate. Insilico did this by targeting IPF, or idiopathic pulmonary fibrosis.
Through an SMAF lens, this is the strategic move. The company did not stay at the level of “AI can discover drugs.” It selected a disease scenario where the technology could be tested against real-world evidence, regulatory, partnership, and business requirements. This is why Rentosertib matters.
The asset moves the conversation from AI discovery speed to a harder question:
Can an AI-enabled biotech company turn discovery into validated assets, strategic partnerships, and repeatable business value?
Business and Narrative Maturity: “AI-Discovered Drug” Is No Longer Enough
In the early AI wave, “AI-discovered drug” was enough to capture attention. By 2026, it will no longer be enough to sustain the premium.
Markets now want specifics: the target, the indication, the endpoint, the regulatory path, the partner logic, and the platform’s repeatability.
For founders, the lesson is clear: AI novelty may open the door. But only a mature business scenario keeps the door open.
A strong narrative does not exaggerate certainty. It shows how technological possibility becomes clinical evidence, commercial value, and investor confidence.
2. Cross-Border Maturity: Speed ≠ Trust
Insilico is especially important because it sits across different geographies, capital systems, and operating logics.
Its links to Hong Kong and China’s biotech infrastructure give it access to real advantages: engineering talent, biotech clusters, automation capacity, scientific speed, cost-efficient R&D execution, and increasingly sophisticated capital-market infrastructure.
But global commercialization requires another layer.
It requires regulatory confidence, clinical transparency, pharma trust, investor communication, data governance, and geopolitical risk management.
This is where globally operating AI biotech companies with strong Hong Kong, China, or Asia-linked R&D networks face a hidden challenge.
Cross-Border Maturity: Speed ≠ Trust
Speed is not enough.
To win globally, they must translate technology, evidence, governance, and narrative into a form that global stakeholders can trust.
Through an SMAF lens, this is not just an expansion strategy. It is a maturity test.
The ultimate question for cross-border founders is: “Can this company become globally legible, credible, and trusted?”
3. The SMAF Takeaway: A Conditional Premium
Did Insilico Medicine pass the SMAF test? Partially.
Insilico has passed some important parts of the SMAF test:
Its AI drug discovery capability appears strong.
Its story has moved from a broad AI-discovery promise to a more concrete disease pathway through Rentosertib and IPF.
The Eli Lilly collaboration strengthens external validation and commercial credibility.
But it has not yet fully passed the broader scenario maturity test.
The remaining question is not whether the technology is impressive.
It is whether the surrounding scenario is mature enough to support repeatable clinical progress, durable commercial value, capital-market confidence, and globally credible governance.
The SMAF Takeaway: A Conditional Premium
That is why the AI-drug premium is not dead. It is being repriced.
Markets will no longer reward AI capability alone. The premium must now be earned through clinical progress, pharma validation, financial discipline, and globally credible governance.
For cross-border biotechs, the real bridge is not just market access. It is the ability to translate speed into trust, science into evidence, and platform ambition into globally legible value.
This is the core question behind the Mans International SMAF Sprint 2026:
If the technology works, is the surrounding scenario mature enough to turn it into adoption, revenue, and durable strategic value?
This is the exact diagnostic we run at the Mans International SMAF Sprint 2026.
At Mans International, we use the Scenario Maturity Assessment Framework (SMAF) to help founders, investors, and strategic leaders diagnose one critical question: If the technology works, is the surrounding scenario mature enough to convert it into adoption, revenue, and durable strategic value?
What Huawei’s Tau Scaling Law and DeepSeek V4 Reveal About the New AI Moat
Constraint Is the Ultimate Strategy Test
The AI race is entering a new phase. For years, AI advantage seemed to belong to those who could scale the biggest models, compute, chips, data centers, and capital. But DeepSeek and Huawei point to a different strategic reality.
The next AI advantage may not come from one isolated breakthrough. It may come from the ability to redesign the whole system under constraints.
That is why they matter to founders. They are not only technology stories. They are scenario maturity stories.
They show that real AI defensibility comes from system alignment: model, chip, data, workflow, cost structure, infrastructure, regulation, and market readiness working together.
This is the shift the Scenario Maturity Assessment Framework, or SMAF, is designed to evaluate: not whether a technology is impressive in isolation, but whether the surrounding scenario is mature enough to convert that technology into commercial power.
Huawei’s Tau Scaling Law: From Component Thinking to System Thinking
At IEEE ISCAS 2026, Huawei’s He Tingbo introduced Tau Scaling Law, a proposed path for semiconductor progress as Moore’s Law becomes harder to sustain.
The strategic idea is simple: progress no longer depends only on making each component smaller. It also depends on making the whole system faster, better connected, and more coordinated.
Huawei’s Tau Scaling Law: From Component Thinking to System Thinking
For decades, chips improved through component-level scaling: smaller nodes, more transistors, higher density, and lower cost per computation. But when physical limits and geopolitical constraints restrict the old path, the question changes.
Can performance improve through architecture, integration, packaging, interconnects, software optimization, and full-stack coordination? Huawei’s answer is yes.
Whether every technical claim is fully validated remains to be seen. But the strategic signal is clear: when the direct path is blocked, advantage comes from redesigning the system.
This is why Huawei’s Tau Scaling Law matters beyond semiconductors. It reflects a broader strategic shift from component superiority to system maturity — a lesson every founder and investor should understand.
DeepSeek V4: From Model Power to Cost-Performance Fit
DeepSeek shows the same shift from the model side. The real lesson is not simply that China has produced another strong AI model. It is that model efficiency, hardware adaptation, and cost compression are starting to work together in commercially meaningful ways.
DeepSeek V4’s reported adaptation to Huawei Ascend chips signals a larger ecosystem strategy: models, domestic hardware, infrastructure, and cost-performance logic evolving together. That is different from a pure model race.
DeepSeek V4: From Model Power to Cost-Performance Fit
A pure model race asks: Who has the most powerful model?
A scenario maturity lens asks: Where can intelligence be deployed reliably, affordably, repeatedly, and profitably?
This is the more important question for founders.
Because cheaper intelligence does not automatically create a better business. Lower inference cost does not automatically create willingness to pay. Open-source momentum does not automatically create defensibility.
The real question is whether a specific market scenario is mature enough to turn intelligence into revenue, retention, workflow advantage, or strategic control.
That is where SMAF becomes useful.
The New AI Moat Is Scenario Maturity
DeepSeek and Huawei challenge a dangerous assumption in the AI application layer: that access to a strong model is enough. It is not.
As foundational intelligence becomes cheaper, faster, and more widely available, the moat shifts from model access to scenario maturity.
The New AI Moat Is Scenario Maturity
In SMAF, a mature AI scenario is not defined by technical excitement. It is defined by alignment across four dimensions:
Narrative Maturity: Can users, buyers, and investors quickly understand why this matters now?
Business Maturity: Who pays, why now, and what budget is unlocked?
Workflow Maturity: Does the AI fit how users actually work, decide, buy, and adopt?
Data Maturity: Can the system learn from relevant, repeatable data?
This is why many AI startups fail despite impressive demos. They build around capability before proving scenario maturity.
DeepSeek and Huawei show a different discipline: both respond to constraints through system design.
DeepSeek addresses compute and cost constraints through model efficiency and hardware adaptation. Huawei addresses semiconductor constraints through architecture, integration, and full-stack optimization.
The lesson for founders is not to copy them. It is to identify your own constraint. Is your real bottleneck model quality, data access, workflow adoption, compliance, trust, distribution, cost, budget ownership, or integration? Until you know the constraint, you do not know the strategy.
Constraint does not kill strategy. Constraint reveals strategy.
Constraint reveals strategy
If you are building or investing in the AI application layer, SMAF helps answer a harder question: Which scenario is mature enough to turn intelligence into durable value?
At Mans International, I work with a selected group of founders and investors to assess when an AI opportunity has matured enough to build a real business — and where East‑West ecosystem gaps offer strategic advantage.
